Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Nicox SA | 21 |
| 2 | Pfizer Inc | 9 |
| 3 | Acadia Pharmaceuticals Inc | 7 |
| 4 | Daiichi Sankyo Co Ltd | 4 |
| 5 | Washington University in St. Louis | 3 |
| 6 | Kenvue Inc | 2 |
| 7 | Selvita SA | 2 |
| 8 | Alcon Inc | 1 |
| 9 | Avalo Therapeutics Inc | 1 |
| 10 | Hospital for Sick Children | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 101 |
| 2 | A61K | Medicinal preparations | 98 |
| 3 | C07D | Heterocyclic compounds | 36 |
| 4 | Y02A | Climate change adaptation | 22 |
| 5 | C07C | Acyclic and carbocyclic compounds | 16 |
| 6 | A61M | Devices for introducing media into the body | 12 |
| 7 | C07K | Peptides | 12 |
| 8 | A61L | Sterilising / disinfecting materials | 11 |
| 9 | C08L | Polymer compositions (blends) | 11 |
| 10 | C08B | 3 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method for treatment of retinal diseases | 2000 | University of California | 165 |
| Dopamine analog amide | 2002 | Daiichi Sankyo Co Ltd | 121 |
| Preventing neuronal degeneration in Alzheimer's disease | 1999 | Washington University in St. Louis | 115 |
| Dopamine analog amide | 2001 | Daiichi Sankyo Co Ltd | 106 |
| Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) | 1997 | Washington University in St. Louis | 122 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | John E. Piletz | University of Mississippi Medical Center | 7 |
| 2 | He Zhu | University of Mississippi Medical Center | 4 |
| 3 | Patricia Dranchak | National Center for Advancing Translational Sciences | 4 |
| 4 | Paul Ernsberger | Case Western Reserve University | 4 |
| 5 | James Inglese | National Center for Advancing Translational Sciences | 4 |
| 6 | Jens Scholz | University of Lübeck | 3 |
| 7 | Anton Simeonov | National Center for Advancing Translational Sciences | 3 |
| 8 | Ajit Jadhav | National Center for Advancing Translational Sciences | 3 |
| 9 | Adam Yasgar | National Institutes of Health | 2 |
| 10 | Danica Agbaba | University of Belgrade | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. | 1993 | 245 | Eicosanoids and Hypertension Pharmacology |
| Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression | 2003 | 133 | Neurotransmitter Receptor Influence on Behavior |
| Membrane localization and guanine nucleotide sensitivity of medullary I1-imidazoline binding sites | 1997 | 38 | Neuroscience and Neuropharmacology Research |
| Evidence for the Existence of Imidazoline‐Specific Binding Sites in Synaptosomal Plasma Membranes of the Bovine Brainstem | 1998 | 35 | Neuroscience and Neuropharmacology Research |
| p-[125I]iodoclonidine, a novel radiolabeled agonist for studying central alpha 2-adrenergic receptors. | 1990 | 31 | Neuropeptides and Animal Physiology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of p-Iodoclonidine?
Which organizations hold the most patents involving p-Iodoclonidine?
What are the major research areas covered by patents related to p-Iodoclonidine?
Who are the most prolific authors publishing on p-Iodoclonidine?
How has research activity on p-Iodoclonidine changed in recent years?